Search
BioVie Inc
BIVIAdd to Watchlist
1.950USD
-0.230-10.55%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.71MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-10.55%
5 Days
+0.52%
1 Month
+13.37%
6 Months
+46.62%
Year to Date
+68.10%
1 Year
-79.69%
Key Figures
2.220Open
2.225High
187.07KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
2.48%Turnover Ratio
2.180Prev. Close
1.945Low
255.67KTurnover
LossP/E Static
0.94P/B
0.00%Div Yield TTM
-94.45%ROA
12.10052wk High
1.79Volume Ratio
-17.91MNet Profit
7.54MShares
-3.7898EPS TTM
0.69Beta
-106.67%ROE
1.06052wk Low
12.84%Amplitude
--Gross Margin
14.71MMarket Cap
4.70Reward/Risk
5.69%Risk Rate
TradingKey Stock Score of BioVie Inc
Currency: USD Updated: 2026-07-02Key Insights
BioVie Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 197 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioVie Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BioVie Inc Highlights
StrengthsRisks
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Fairly Valued
The company’s latest PE is -0.51, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.18M shares, decreasing 23.27% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.57.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
5.000
Target Price
+129.36%
Upside Space
BioVie Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioVie Inc Info
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Ticker SymbolBIVI
CompanyBioVie Inc
CEODo (Viet Cuong Viet)
Websitehttps://www.bioviepharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of BioVie Inc (BIVI)?
The current price of BioVie Inc (BIVI) is 1.95.
What is the symbol of BioVie Inc?
The ticker symbol of BioVie Inc is BIVI.
What is the 52-week high of BioVie Inc?
The 52-week high of BioVie Inc is 12.10.
What is the 52-week low of BioVie Inc?
The 52-week low of BioVie Inc is 1.06.
What is the market capitalization of BioVie Inc?
The market capitalization of BioVie Inc is 14.71M.
Is BioVie Inc (BIVI) currently rated as Buy, Hold, or Sell?
According to analysts, BioVie Inc (BIVI) has an overall rating of Buy, with a price target of 5.00.
What is the Earnings Per Share (EPS TTM) of BioVie Inc (BIVI)?
The Earnings Per Share (EPS TTM) of BioVie Inc (BIVI) is -12.12.